Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma

Area of Science:

• Oncology
• Bone Biology
• Neuroscience

Background:

• Multiple myeloma (MM) involves plasma cell accumulation and lytic bone lesions.
• Mechanisms of enhanced bone resorption in MM are not fully understood.
• Brain-derived neurotrophic factor (BDNF) previously linked to MM cell proliferation and migration.

Purpose of the Study:

• Investigate BDNF's role in MM cell-induced osteolysis.
• Determine if BDNF contributes to the bone disease in multiple myeloma.

Main Methods:

• Measured BDNF levels in MM patients' bone marrow plasma.
• Assessed osteoclast formation using patient plasma and recombinant BDNF.
• Utilized neutralizing antibodies and Trk inhibitor (K252a) to block BDNF signaling.
• Correlated BDNF levels with osteoclast stimulatory factors (MIP-1α, RANKL).

Main Results:

• BDNF levels were elevated in MM patients and correlated with bone disease extent.
• MM patient plasma enhanced osteoclast formation, blocked by anti-BDNF antibody.
• Recombinant BDNF directly promoted osteoclast formation and bone resorption.
• BDNF signaling in osteoclasts occurs via the TrkB receptor.
• BDNF levels correlated with MIP-1α and RANKL, key osteoclast factors.

Conclusions:

• BDNF plays a significant role in osteoclast activation and bone resorption in MM.
• BDNF contributes to the development of myeloma bone disease.
• Targeting the BDNF-TrkB pathway may be a therapeutic strategy for MM bone complications.